Eiger BioPharmaceuticals, Inc. (EIGR) Set to Announce Quarterly Earnings on Monday
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) will issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($1.28) per share for the quarter.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.05). On average, analysts expect Eiger BioPharmaceuticals to post $-5.35 EPS for the current fiscal year and $-5.02 EPS for the next fiscal year.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) opened at 11.60 on Monday. The company’s market cap is $97.06 million. The firm’s 50-day moving average is $11.55 and its 200 day moving average is $8.81. Eiger BioPharmaceuticals, Inc. has a 12-month low of $6.10 and a 12-month high of $13.95.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/30/eiger-biopharmaceuticals-inc-eigr-set-to-announce-quarterly-earnings-on-monday.html.
A number of research firms have recently weighed in on EIGR. Oppenheimer Holdings, Inc. set a $34.00 price objective on Eiger BioPharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research raised Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Monday, October 16th. Roth Capital began coverage on Eiger BioPharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $35.00 price objective for the company. Wedbush reissued a “buy” rating on shares of Eiger BioPharmaceuticals in a research note on Wednesday, October 25th. Finally, ValuEngine raised Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $30.43.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.